Regeneron temporarily extends EYLEA® (aflibercept) Injection payment terms

In response to the COVID-19 pandemic, Regeneron temporarily extends EYLEA® (aflibercept) Injection physician payment terms to 150 days, subject to distributor qualification.

COVID-19 is having a significant impact on the healthcare community and in some instances, it is limiting patient access to essential care. In response to the unprecedented situation facing physicians and their patients during this pandemic, Regeneron has temporarily extended payment terms for EYLEA purchases to authorized distributors. This has no impact on our current EYLEA return policies.

Physicians may now temporarily be eligible for payment terms of up to 150 days (previously 100 days), subject to distributor qualification. Please verify the timing and specific dating terms that apply to your office with your authorized distributors of record.

Regeneron is working with its authorized distributors of record to apply these new temporary terms for EYLEA (vial or pre-filled syringe) purchased on or after March 1, 2020. We aim to implement these new terms by April 1, 2020 though these temporary payment terms will be retroactively implemented, as noted above. These temporary payment terms are subject to change and will continue to be evaluated as the COVID-19 situation evolves.

Please contact your specialty distributor with questions or to apply these new terms.

For more on Regeneron’s scientific efforts to help address COVID-19, please visit our website:

Ordering EYLEA

EYLEA4U® logo.

Authorized Distributors

EYLEA is available through a number of different sources. Contact one of our Authorized Distributors listed below to order EYLEA and receive it by the next business day.*

Regeneron does not recommend the use of any particular listed distributor. Subject to distributor qualification.

*Orders received prior to 7 PM Eastern Time Monday–Thursday are typically processed on the same day and scheduled for delivery the next business day. Order received on Friday will typically be delivered the following Monday.

Specialty pharmacy providers

As an option, or if instructed by the payer, EYLEA may be obtained through our network of specialty pharmacy providers.

Regeneron does not recommend the use of any particular listed specialty pharmacy.

Wholesale Acquisition Cost Discount

Please contact your distributor or your Regeneron representative for additional information about the Wholesale Acquisition Cost (WAC) Discount

The discount is available to community-based physicians in freestanding, physician-owned solo or group practices who are treating patients on an outpatient basis and who purchase EYLEA directly from the Authorized Distributors listed above. This discount applies only to eligible purchasers ordering from an Authorized Distributor.

The discount is intended to constitute a discount as such term is defined in 42 U.S.C. § 1320a-7(b)(3) and 42 C.F.R. § 1001.952(h). As such, it must be reported by any eligible purchaser in any costs claimed or charges made to any federal healthcare program, including Medicare and Medicaid.

This discount for EYLEA® (aflibercept) Injection is available to eligible community-based physicians in freestanding, physician-owned solo or group practices who are treating patients on an outpatient basis and who purchase EYLEA directly from participating authorized distributors ("Eligible Community Physicians") in accordance with the following terms:*

Requires Health Industry Number (HIN)
The discount is a flat off-invoice discount based on the current EYLEA WAC only for Eligible Community Physicians with a valid practice HIN.

HIN is a unique ID for identifying healthcare trade partners, managed by the Health Industry Business Communications Council (HIBCC). If you do not have an HIN or are not sure if you have an HIN, contact your distributor for assistance.

You may also register for a HIN through HIBCC:

No Enrollment
The discount is not subject to any enrollment requirements.

Applies to All Eligible Purchases
The discount will apply to all purchases made by Eligible Community Physicians through a participating authorized distributor.

Only Eligible Community Physicians
The discount does not apply to hospitals, specialty pharmacies, retail pharmacies, compounding pharmacies, distributors, wholesalers, Federal government, Department of Defense, Indian Health Services, Veteran's Affairs, local governments, group purchasing organizations, managed care organizations, home care providers, long term care providers, donation accounts, pharmaceutical manufacturers, outside research organizations or veterinary providers.

Effective Date of Discount
The discount is effective March 18, 2019.

*Terms and availability are subject to change at Regeneron's discretion.

Please note that participating physicians have an obligation to comply with all retention, disclosure and reporting requirements regarding the value of any discounts or price concessions paid or received, pursuant to 42 U.S.C. § 1320a-7(b)(3) and 42 C.F.R. § 1001.952(h) and all other applicable federal and state laws and regulations. As such, it must be reported by any Eligible Community Physician in any costs claimed or charges made to any federal health care program, including Medicare and Medicaid.

Have a question about the discount through distributors for EYLEA?
We're here for you. Contact EYLEA4U® at 1-855-EYLEA4U (1-855-395-3248), Option 5, Monday–Friday 9 AM–8 PM Eastern Time.


In the event EYLEA is rendered unusable after purchase, product may be returned to Regeneron and replaced in certain circumstances. Returns are subject to adherence to Regeneron policies and procedures regarding the return of product and Regeneron’s right, at its sole discretion, to deny replacement when misuse is suspected. All product should be returned as a condition of replacement.‡,§

EYLEA4U® contact information

Call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 3, to obtain the appropriate forms and list of required documents

If vial/pre-filled syringe (PFS) is broken
Submit pictures
documenting the damage.

If vial/PFS is intact
After submitting required paperwork, return per instructions in retrieval kit sent to your practice.

Call EYLEA4U at 1-855-EYLEA4U, Option 3, to obtain the appropriate forms and list of required documents. If vial is broken submit pictures documenting the damage. If vial is intact return to the address provided by EYLEA4U.
  • Subject to certain exceptions in accordance with Regeneron policy.
  • §Broken vial(s)/PFS do not have to be returned, but pictures documenting the damage should be submitted.

Product return procedure

  1. Contact EYLEA4U, 1-855-EYLEA4U (1-855-395-3248) and select Option 3
  2. Complete the Return Product Eligibility Certification form in its entirety and return with the following:
    • a. Proof of Purchase for units being returned
    • b. In the case of broken vial(s)/PFS, pictures documenting the damage
  3. Completed forms and supporting documents may be faxed to (615) 827-0164 or emailed to
  4. Hold/quarantine the product to be returned and follow instructions in product retrieval kit
  5. Once approved, replacement product ships within 1 business day of approval

For returns of expired product or product damaged in shipment, contact your distributor for return. For product complaints, please call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 3.

ICD-10 code finder

Use the interactive code finder to quickly find the current ICD-10 codes for EYLEA. To begin, simply answer the following short questions.

The coding information discussed here is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed here may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

For which indication is EYLEA being administered?

  • Wet Age-related Macular Degeneration (Wet AMD)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Macular Edema following Central Retinal Vein Occlusion (CRVO)
  • Macular Edema following Branch Retinal Vein Occlusion (BRVO)
{{DownloadFormModel.OutputFileName}}.zip  {{DownloadFormModel.DownloadSize}} MB

Patient pamphlets

Provide your patients more information on their indication, EYLEA, and the support available through EYLEA4U.

EYLEA4U® logo.

EYLEA4U e-Portal

Your one-stop, online destination for reimbursement and patient support.

  • Requires registration and e-signature setup.
Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
Patient support for EYLEA.
Patient Support

We're committed to help ensure
your eligible patients have
access to EYLEA.

Find out more
EYLEA news, events, and more.

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.